Navigation Links
National experts from the John Theurer Cancer Center will present 31 studies at the 2011 ASH Meeting
Date:12/1/2011

Hackensack, N.J. (December 1, 2011) - The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

More than half of the John Theurer Cancer Center presentations showcased at the ASH Annual Meeting have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, multi-center, international trials in collaboration with leading cancer institutions such as the National Cancer Institute, MD Anderson, Dana-Farber, Mayo Clinic, and Memorial Sloan-Kettering.

"Personalizing therapies will certainly play a growing role in the practice of oncology," said Andre Goy, M.D., M.S., chairman and director, chief of lymphoma, and director, clinical and translational cancer research. "Our center is part of many studies researching novel therapies as well as the identification of biomarkers predictive of outcomes in cancer."

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. The research presented by the John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia.

Seven John Theurer Cancer Center physicians are first or senior authors, including Dr. Goy; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Anthony Mato, M.D., oncologist, lymphoma; Joshua Richter, M.D., oncologist, multiple myeloma; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma; and David Vesole, M.D., Ph.D., co-chief and director of research, multiple myeloma.

John Theurer Cancer Center experts
'/>"/>

Contact: Amy Leahing
amy.leahing@zibbel.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology news :

1. Registration for the XIX International AIDS Conference (AIDS 2012) opens Dec. 1
2. Arizona Engineering associate professor earns national recognition
3. Iowa State engineers establish national panel to advance a carbon negative economy
4. International team to drill beneath massive Antarctic ice shelf
5. Story tips from the US Department of Energys Oak Ridge National Laboratory, November 2011
6. Marine Biological Laboratory Course Director Eric Davidson awarded International Prize for Biology
7. Veritec and National Identity Solutions (NIS) Sign Significant License Agreement Entering Into a $500 Billion Marketplace
8. Journal of the Chinese Chemical Society expands international reach with Wiley-VCH
9. International symposium explores genetic link to mesothelioma and other cancers
10. Neurotechnology Releases MegaMatcher Accelerator 4.0 for National-scale Fingerprint and Iris Biometric Identification
11. NOAA releases status on Florida Keys National Marine Sanctuary marine resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... types are essential for studies of their development ... A Laboratory Manual provides step-by-step protocols for isolating ... them under conditions that closely resemble those in ... dissect the brain, spinal cord, and other tissues; ...
... Did you know that crystals form the basis for the penetrating ... the future in solar energy technology? Crystals are at the ... formed naturally, but manufactured to form alloys, such as indium gallium ... LEDs, for illumination in the visible range, and of laser diodes ...
... grams of essential amino acids taken twice daily for a week ... mean age 69, recover faster and with much less muscle atrophy ... detailed in a paper now online ahead of print in the ... -- could spell relief and speed recovery for a growing population ...
Cached Biology News:ASU, Georgia Tech create breakthrough for solar cell efficiency 2Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... , DARTMOUTH, NS , July 12 /PRNewswire/ - ... Omega-3, EPA/DHA, food and dietary supplement ingredients, announces today the acquisition ... Essentials (GAT) Omega-3 microencapsulation-emulsion technology. , ... As a result of the agreement, ONC acquired ...
... July 12, 2010 Points to,Novel Pathway for Drug Discovery, ... Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at deCODE genetics and academic colleagues ... and North America today,report the discovery of a common single-letter ...
... , , ... Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing ... clinical advisory panel (the "Panel"). , , ... Panel of international experts with special expertise in ovarian cancer has been charted ...
Cached Biology Technology:Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 2Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4Quest PharmaTech Announces Formation of Clinical Advisory Panel 2Quest PharmaTech Announces Formation of Clinical Advisory Panel 3
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Biology Products: